- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04089579
hCT-MSC in Children With Autism Spectrum Disorder (IMPACT)
A Phase II Study of hCT-MSC, an Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this double blinded Phase II study is to determine the efficacy of human umbilical cord tissue-derived mesencymal stromal cells (hCT-MSC), administered in two different dosing strategies, in children with autism spectrum disorder (ASD).
This study will be enrolling children with ASD, aging 4-11 years of age. Qualifying subjects will undergo neuropsychological evaluation, EEG testing, eye tracking, CVA assessments, and infusion of study product. Subjects will be randomized to one of two study arms; 1) a single infusion of 6.0x106 cells/Kg at baseline, followed by a blinded placebo infusion at six months or, 2) Placebo infusion at baseline, followed by an intravenous dose of 6x106 cells/Kg at six months.
The primary endpoint of this study is the change in social communication skill from baseline to six months. The potential risks associated with infusion of MSCs include a reaction to the product (rash, shortness of breath, wheezing, difficulty breathing, hypotension, swelling around the mouth, throat or eyes, tachycardia, diaphoresis), transmission of infection, and HLA sensitization.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age ≥ 4 years to < 12 years (11 years, 364 days) at the time of consent
- Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using the DSM-5 Checklist as informed by the Brief Observation of Symptoms of Autism (BOSA) and the Autism Diagnostic Interview-Revised (ADI-R)
- Fragile X testing performed and negative; CMA and/or whole exome sequencing performed and results not linked to autism diagnosis
- Stable on current psychiatric medication regimen (dose and dosing schedule) for at least 2 months prior to infusion of study product
- Normal absolute lymphocyte count (≥1200/uL for African American participants and ≥1500/uL for all other participants)
- GAI ≥ 65 via cognitive testing by study personnel
- Participant and parent/guardian are English speaking
- Able to travel to Duke University two times (baseline, six months), and parent/guardian is able to participate in interim surveys and interviews
- Parental/guardian consent from at least one parent/guardian
Exclusion Criteria
General:
- Review of medical records and/or screening assessments indicates ASD diagnosis and/or GAI > 65 not confident
- Known diagnosis of any of the following coexisting psychiatric conditions: depression, bipolar disorder, schizophrenia, obsessive compulsive disorder associated with bipolar disorder, Tourette syndrome
- Screening data suggests that participant would not be able to comply with the requirements of the study procedures as assessed by the study team
- Family is unwilling or unable to commit to participation in all study-related assessments, including protocol follow up
- Sibling is enrolled in this (Duke IMPACT) study
Genetic:
- Records indicate that child has a known genetic syndrome such as (but not limited to) Fragile X syndrome, neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cystic fibrosis, muscular dystrophy or a genetic defect definitively known to be associated with ASD
- Known pathogenic mutation or copy number variation (CNV) associated with ASD (e.g., 16p11.2, 15q13.2, 2q13.3)
Infectious:
- Known active CNS infection
- Evidence of uncontrolled infection based on records or clinical assessment
- Known HIV positivity
- Exposure to COVID-19 in the preceding 14 days or positive COVID-19 test in the previous 28 days. Subjects with a past history of infection with COVID-19 must be symptom-free for 14 days prior to the initial visit.
Medical:
- Known metabolic disorder
- Known mitochondrial dysfunction
- History of unstable epilepsy or uncontrolled seizure disorder, infantile spasms, Lennox Gastaut syndrome, Dravet syndrome, or other similar chronic seizure disorder
- Active malignancy or prior malignancy that was treated with chemotherapy
- History of a primary immunodeficiency disorder
- History of autoimmune cytopenias (i.e., ITP, AIHA)
- Coexisting medical condition that would place the child at increased risk for complications of study procedures
- Concurrent genetic or acquired disease or comorbidity(ies) that could require a future stem cell transplant
- Significant sensory (e.g., blindness, deafness, uncorrected hearing impairment) or motor (e.g., cerebral palsy) impairment
- Impaired renal or liver function as determined by serum creatinine >1.5mg/dL or total bilirubin >1.3mg/dL, except in patients with known Gilbert's disease
- Significant hematologic abnormalities defined as: Hemoglobin <10.0 g/dL, Platelets <150 x 10e9/uL, WBC <3,000 cells/mL, ALC <1200/uL for African Americans or <1500/uL for all other participants.
- Evidence of clinically relevant physical dysmorphology indicative of a genetic syndrome as assessed by the PIs or other investigators, including a medical geneticist and psychiatrists trained in identifying dysmorphic features associated with neurodevelopmental conditions.
Current/Prior Therapy:
a. Availability of a banked, qualified autologous cord blood unit or parents deferred use of qualified, autologous cord blood unit b. History of prior cell therapy c. Current or prior use of IVIG or other anti-inflammatory medications with the exception of NSAIDs d. Current or prior immunosuppressive therapy i. No systemic steroid therapy that has lasted >2 weeks, and no systemic steroids within 3 months prior to enrollment. Topical and inhaled steroids are permitted.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSC
One dose of 6x10e6 cells/kg administered intravenously.
|
Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors.
One dose of 6x10e6 cells/kg administered intravenously.
|
Placebo Comparator: Placebo Infusion
Placebo infusion
|
Placebo comparative infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change on the Socialization and Communication Subscale Standard Scores on the Vineland Behavior Scales
Time Frame: Baseline, 6 months
|
The primary outcome measure is the mean of the change on the Socialization and Communication Subscale Standard Scores on the Vineland Adaptive Behavior Scales (VABS-3).
The primary endpoint is the change on this outcome measure from baseline to six months.
|
Baseline, 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in VABS-3 Socialization Standard Score
Time Frame: Baseline, 6 months
|
Change in VABS-3 (Vineland Adaptive Behavior Scales) Socialization Standard Score
|
Baseline, 6 months
|
Change in VABS-3 Communication Standard Score
Time Frame: Baseline, 6 months
|
Change in VABS-3 (Vineland Adaptive Behavior Scales) Communication Standard Score
|
Baseline, 6 months
|
Change in CGI-Severity score
Time Frame: Baseline, 6 months
|
Clinical Global Impression- Severity Scale
|
Baseline, 6 months
|
CGI-Intervention score
Time Frame: Baseline, 6 months
|
Clinical Global Impression- Impression
|
Baseline, 6 months
|
Change in the Pediatric Quality of Life Scale
Time Frame: Baseline, 6 months
|
Pediatric Quality of Life Scale, raw scale range of 0-2300 with higher scores indicating a higher quality of life (better outcome)
|
Baseline, 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of infusion reactions
Time Frame: Baseline, 6 months
|
Assess for infusion reactions
|
Baseline, 6 months
|
Incidence and severity of product-related infections
Time Frame: Baseline, 6 months
|
Assess for infections directly related to the study product infusions
|
Baseline, 6 months
|
Evidence of formation of anti-HLA antibodies
Time Frame: Baseline, 6 months, 12 months
|
Assess for anti-HLA antibodies
|
Baseline, 6 months, 12 months
|
Incidence and severity of graft versus host disease
Time Frame: 6 months, 12 months
|
Assess for signs and symptoms of graft versus host disease
|
6 months, 12 months
|
Incidence and severity of unexpected adverse events related to the study product
Time Frame: Baseline, 6 months, 12 months
|
Assess for study related and unexpected adverse events
|
Baseline, 6 months, 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lauren Franz, MBChB, Duke University
- Principal Investigator: Beth Shaz, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00113011
- Pro00102894 (Other Identifier: Duke IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hoffmann-La RocheActive, not recruitingAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
-
Hospital Universitario Dr. Jose E. GonzalezUnknownAutism | Autism SpectrumMexico
-
National Taiwan University HospitalCompletedAutism Spectrum Disorder High-FunctioningTaiwan
Clinical Trials on Cord Tissue Mesenchymal Stromal Cells
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); Stem Cell Network; Ontario Institute...RecruitingBronchopulmonary DysplasiaCanada
-
Charles CoxCBR Systems, Inc.Not yet recruitingPost-Acute COVID-19 SyndromeUnited States
-
Universidad de los Andes, ChileUnknownOsteoarthritis, KneeChile
-
Joanne Kurtzberg, MDWithdrawnMultisystem Inflammatory Syndrome in ChildrenUnited States
-
Mayo ClinicRecruitingKidney TransplantUnited States
-
Instituto de Investigación Sanitaria de la Fundación...Hospital General Universitario Gregorio Marañon; Clinica Universidad de Navarra... and other collaboratorsSuspended
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Cell Factory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Laboratorio...CompletedIdiopathic Nephrotic Syndrome | Nephrotic Syndrome in Children | Steroid-Dependent Nephrotic SyndromeItaly
-
Translational BiosciencesWithdrawnOsteoarthritis of the KneePanama
-
Leiden University Medical CenterCompletedRejection | Graft LossNetherlands
-
Postgraduate Institute of Medical Education and...UnknownRenal Transplant RejectionIndia